Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 250

Showing 1-25 of 250 citing articles:

Updated mechanisms of MASLD pathogenesis
Yuxuan Li, Peipei Yang, Jialu Ye, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 39
Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
Karli R. LeFort, Wiramon Rungratanawanich, Byoung‐Joon Song
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 36
Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease
Sophie Gensluckner, Bernhard Wernly, Christian Datz, et al.
Antioxidants (2024) Vol. 13, Iss. 2, pp. 208-208
Open Access | Times Cited: 22
Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review
Basma Hossam Abdelmonem, Noha M. Abdelaal, Eman K. E. Anwer, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1467-1467
Open Access | Times Cited: 18
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials
Tushar Khare, Karina Liu, Lindiwe Oslee Chilambe, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 306-306
Open Access | Times Cited: 4
Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus
Mengmeng Hu, Jingyu Yang, Beibei Gao, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
Emerging role of aging in the progression of NAFLD to HCC
Yongyuan He, Yinghong Su, Chengcheng Duan, et al.
Ageing Research Reviews (2022) Vol. 84, pp. 101833-101833
Closed Access | Times Cited: 45
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 30
Hepatic insulin receptor: new views on the mechanisms of liver disease
Wang‐Hsin Lee, Sonia M. Najjar, C. Ronald Kahn, et al.
Metabolism (2023) Vol. 145, pp. 155607-155607
Open Access | Times Cited: 29
Advances and perspectives in fluorescent probes for imaging hepatopathy-related biomarkers
Quan Wei, Wenhui Song, Qian Zhang, et al.
Coordination Chemistry Reviews (2023) Vol. 497, pp. 215407-215407
Closed Access | Times Cited: 29
The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
Milena Vesković, Nikola Šutulović, Dragan Hrnčić, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 9084-9102
Open Access | Times Cited: 28
Oxidative Stress and MicroRNAs in Endothelial Cells under Metabolic Disorders
Morgan Minjares, Wendy Wu, Jie‐Mei Wang
Cells (2023) Vol. 12, Iss. 9, pp. 1341-1341
Open Access | Times Cited: 25
Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism
Tingting Zhou, Ligang Cao, Yimei Du, et al.
PeerJ (2023) Vol. 11, pp. e15225-e15225
Open Access | Times Cited: 23
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice
Hassam Ali, Muhammad Shahzil, Vishali Moond, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 61-61
Open Access | Times Cited: 12
Dietary chlorogenic acid alleviates high-fat diet-induced steatotic liver disease by regulating metabolites and gut microbiota
Yujuan Yu, Fumao Zeng, Peiheng Han, et al.
International Journal of Food Sciences and Nutrition (2024) Vol. 75, Iss. 4, pp. 369-384
Closed Access | Times Cited: 12
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3694-3694
Open Access | Times Cited: 12
Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism (2024) Vol. 155, pp. 155912-155912
Closed Access | Times Cited: 11
The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Paulina Vidal‐Cevallos, Adriana P. Sorroza-Martínez, Norberto C. Chávez‐Tapia, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4397-4397
Open Access | Times Cited: 9
Supplementation of Silymarin Alone or in Combination with Salvianolic Acids B and Puerarin Regulates Gut Microbiota and Its Metabolism to Improve High-Fat Diet-Induced NAFLD in Mice
Xin Wang, Yufeng Jin, Can Di, et al.
Nutrients (2024) Vol. 16, Iss. 8, pp. 1169-1169
Open Access | Times Cited: 8
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites (2024) Vol. 14, Iss. 4, pp. 218-218
Open Access | Times Cited: 8
AlphaFold-Based AI Docking Reveals AMPK/SIRT1-TFEB Pathway Modulation by Traditional Chinese Medicine in Metabolic-Associated Fatty Liver Disease
Lulu Zhang, Yi Zheng, Mingyan Shao, et al.
Pharmacological Research (2025), pp. 107617-107617
Open Access | Times Cited: 1
Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sara Jarmakiewicz-Czaja, Aneta Sokal, Rafał Filip
Medicina (2025) Vol. 61, Iss. 2, pp. 192-192
Open Access | Times Cited: 1
Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation
Tingwan Du, Xiang Lian, Jingjing Zhang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 21
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9677-9677
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top